Literature DB >> 6150036

Inhibition of smooth muscle actin-activated myosin Mg2+-ATPase activity by caldesmon.

P K Ngai, M P Walsh.   

Abstract

Caldesmon, a major calmodulin- and actin-binding protein of smooth muscle (Sobue, K., Muramoto, Y., Fujita, M., and Kakiuchi, S. (1981) Proc. Natl. Acad. Sci. U. S. A. 78, 5652-5655), has been obtained in highly purified form from chicken gizzard by a modification of a previously published procedure (Ngai, P. K., Carruthers, C. A., and Walsh, M. P. (1984) Biochem. J. 218, 863-870) and was found to cause a significant inhibition of both superprecipitation and actin-activated myosin Mg2+-ATPase activity in a system reconstituted from the purified contractile and regulatory proteins without influencing the phosphorylation state of myosin. This inhibitory effect was seen both in the presence and absence of tropomyosin. A Ca2+-and calmodulin-dependent kinase which catalyzed phosphorylation of caldesmon was identified in chicken gizzard; this kinase is distinct from myosin light-chain kinase. Caldesmon prepared by calmodulin-Sepharose affinity chromatography was contaminated with caldesmon kinase activity and was unable to inhibit actomyosin ATPase activity or superprecipitation. Phosphatase activity capable of dephosphorylating caldesmon was also identified in smooth muscle. These results indicate that caldesmon can inhibit smooth muscle actomyosin ATPase activity in vitro, and this function may itself be subject to regulation by reversible phosphorylation of caldesmon.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6150036

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  70 in total

1.  A novel Ca2+ binding protein associated with caldesmon in Ca2+-regulated smooth muscle thin filaments: evidence for a structurally altered form of calmodulin.

Authors:  G Notarianni; N Gusev; D Lafitte; T J Hill; H S Cooper; P J Derrick; S B Marston
Journal:  J Muscle Res Cell Motil       Date:  2000       Impact factor: 2.698

2.  Ca2+-calmodulin-dependent protein kinase II-dependent activation of contractility in ferret aorta.

Authors:  I Kim; H D Je; C Gallant; Q Zhan; D V Riper; J A Badwey; H A Singer; K G Morgan
Journal:  J Physiol       Date:  2000-07-15       Impact factor: 5.182

Review 3.  Protein kinase C isoenzymes: a review of their structure, regulation and role in regulating airways smooth muscle tone and mitogenesis.

Authors:  B L Webb; S J Hirst; M A Giembycz
Journal:  Br J Pharmacol       Date:  2000-08       Impact factor: 8.739

4.  Myosin regulatory light chain diphosphorylation slows relaxation of arterial smooth muscle.

Authors:  Cindy Sutherland; Michael P Walsh
Journal:  J Biol Chem       Date:  2012-05-31       Impact factor: 5.157

Review 5.  Vascular smooth muscle contractile elements. Cellular regulation.

Authors:  J T Stull; P J Gallagher; B P Herring; K E Kamm
Journal:  Hypertension       Date:  1991-06       Impact factor: 10.190

6.  The effects of phosphorylation of smooth-muscle caldesmon.

Authors:  P K Ngai; M P Walsh
Journal:  Biochem J       Date:  1987-06-01       Impact factor: 3.857

7.  Ontogenesis of myosin light chain phosphorylation in guinea pig tracheal smooth muscle.

Authors:  Pasquale Chitano; Charles L Worthington; Janet A Jenkin; Newman L Stephens; Sylvia Gyapong; Lu Wang; Thomas M Murphy
Journal:  Pediatr Pulmonol       Date:  2005-02

8.  Phosphorylation of caldesmon by smooth-muscle casein kinase II.

Authors:  C Sutherland; B S Renaux; D J McKay; M P Walsh
Journal:  J Muscle Res Cell Motil       Date:  1994-08       Impact factor: 2.698

Review 9.  Caldesmon as a therapeutic target for proliferative vascular diseases.

Authors:  Chi-Ming Hai
Journal:  Mini Rev Med Chem       Date:  2008-10       Impact factor: 3.862

10.  Influence of age, sex, and strength training on human muscle gene expression determined by microarray.

Authors:  Stephen M Roth; Robert E Ferrell; David G Peters; E Jeffrey Metter; Ben F Hurley; Marc A Rogers
Journal:  Physiol Genomics       Date:  2002-09-03       Impact factor: 3.107

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.